Atlas Trials

Dose-response Study of Exendin-9,39 on Glucose Metabolism

Clinical trial NCT01218633 · COMPLETED

Trial details

NCT number
NCT01218633
Sponsor
Adrian Vella
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1
Start date
2011-05-01
Primary completion
2012-07-01
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.